Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 8

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 8
---
 MEASURE VALUE OF OPTIONS GRANTED 

    2025 
  
    Exercise price 
    $9.24 
  
    Expected term (in years) 
     5.5 
  
    Volatility 
     128.4%
  
    Risk free rate 
     4.1%
  
    Dividend yield 
     0%

The
following table presents the exercise price of outstanding stock options as of June 30, 2025:

 SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS 

    Exercise price 
    Options  outstanding 

    $0.01 - $80.00 
     56,047 
  
    $0.01 - $80.00 
     56,047 

    $80.01 or higher 
     48,619 
  
    Total 
     104,666 

NOTE
6: CAPITALIZATION

    a.
    As
    of June 30, 2025 and December 31, 2024, the Company had 200,000,000 shares of common stock authorized and 604,963 and 428,799 shares
    issued and outstanding, respectively. As of June 30, 2025 and December 31, 2024, the Company had 5,000,000 shares of preferred stock
    authorized. There were no shares of preferred stock issued or outstanding as of June 30, 2025 and December 31, 2024. As of June 30,
    2025 and December 31, 2024, there were warrants outstanding to purchase an aggregate of 312,354 and 238,423 shares of common stock,
    respectively. As of June 30, 2025, these warrants were exercisable at a weighted average price of $127.05 and their weighted average
    remaining contractual term was 3.5 years.

    F-9

    b.
    On
    January 16, 2025, the Company completed a private placement offering pursuant to which the Company sold and issued to certain investors
    an aggregate of 75,335 shares of common stock and warrants to purchase 75,335 shares of common stock (the “January 2025 Warrants”).
    The shares and January 2025 Warrants were sold on a combined basis for consideration of $29.82 for one share and one January 2025
    Warrant. The January 2025